This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tecarfarin for preventing venous thromboembolism

< Back

Tecarfarin for preventing venous thromboembolism


Haematology and Blood Products

August 2020

Tecarfarin is in clinical development for the prevention of thromboembolism in patients requiring long-term blood thinning treatment. Venous thromboembolism (VTE) refers to a blood clot that develops in a vein. There are two types of VTE: deep vein thrombosis (DVT) which refers to a blood clot in a vein and pulmonary embolism (PE) which refers to a blood clot that has broken free and travelled to the lungs.. Some patients who have had a VTE require long- term treatment with blood-thinning medication to reduce the risk of VTE recurrence.
Tecarfarin, a vitamin K reductase, is given by oral administration and works by blocking the liver from using vitamin K to make clotting factors. Clotting factors work with blood cells called platelets that trigger the clotting process to form a blood clot. Stopping the activation of these vitamin K dependent clotting factors means the blood takes much longer to clot so there is a decreased risk of VTE. Tecarfarin works in the same way as warfarin, which is the current best treatment option for preventing VTE, but is expected to be safer and deliver more predictable clotting. If licensed, tecarfarin would offer an additional treatment option for preventing VTE in patients who require long-term anticoagulation therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts